Cardiac Conduction System Disease: Clinical Trials

52 trials for Cardiac Conduction System Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 completed, 8 terminated, 7 recruiting, 6 unknown. 52 Phase 2, 11 Phase 1, 8 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 252Completed 23, Terminated 8, Recruiting 7, Unknown 6, Not yet recruiting 3, Withdrawn 3, Active not recruiting 1, Enrolling by invitation 1
Phase 111Completed 4, Terminated 2, Unknown 2, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 38Completed 4, Terminated 2, Recruiting 1, Withdrawn 1

Follow Cardiac Conduction System Disease: new trials by email Literature Review of Cardiac Conduction System Disease trials Research Report on Cardiac Conduction System Disease

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ATR 1072 in Participants With PRKAG2 Syndrome
ATR 1072 - Cardiac Glycogenosis, Cardiomyopathy
Phase 1 / Phase 2RecruitingAtrium Therapeutics372026-09-142026-09-18
Using Mirabegron to Control Arrhythmia-1
Mirabegron - Ventricular Arrhythmias and Cardiac Arrest
Phase 2Not yet recruitingCedars-Sinai Medical Center202026-05-012026-05-06
Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3)
baseline lead-in, THRV-1268 - Long QT Syndrome (LQTS) 2
Phase 2 / Phase 3RecruitingThryv Therapeutics, Inc.842026-03-072026-09-21
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
AGP100 - Catecholaminergic Polymorphic Ventricular Tachycardia
Phase 2RecruitingAgiana Pharmaceuticals102026-01-022025-12-26
A Phase 2 Study of CRD-4730 in CPVT
CRD-4730, Placebo - Catecholaminergic Polymorphic Ventricular Tachycardia
Phase 2RecruitingCardurion Pharmaceuticals, Inc.122025-12-012026-07-09
Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome
Empagliflozin (EMPA) - Brugada Syndrome (BrS)
Phase 2Not yet recruitingNational Taiwan University Hospital102025-09-152025-09-12
To Observe Haemodynamic Parameters Including, Heart Rate, Blood Pressure, Respiratory Rate , and Oxygen Saturation, With or Without Giving Reversal Agent on Extubation, in Patients Receiving Single Shot of Atracurium , and to Observe Post Operative Residual Paralysis and Airway Reflexes in PACU.
Placebo drug ( normal saline ), neostigmine (reversal agent) - Tachycardia, Hypertension
Phase 1 / Phase 2CompletedZiauddin University1002025-03-122025-07-31
N-of-1 in ATS and MEPPC
Flecainide, Flecainide + beta-blocker - Andersen Tawil Syndrome, Multifocal Ectopic Purkinje-related Premature Contractions
Phase 2Not yet recruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)102025-03-012025-01-29
Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions
Varenicline Tartrate Tablets, Placebo - Premature Ventricular Contraction (PVC)
Phase 2CompletedYihan Chen1162025-02-172025-11-19
Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats
Memantine Hydrochloride 10 MG, Placebo - Atrial Premature Beats, Contractions, or Systoles
Phase 2CompletedShanghai East Hospital2562024-08-292025-11-25
The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
Etripamil NS - Paroxysmal Supraventricular Tachycardia
Phase 2RecruitingMilestone Pharmaceuticals Inc.602023-12-112026-07-21
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
CRD-4730, Placebo - CPVT1, Heart Defects, Congenital
Phase 2TerminatedCardurion Pharmaceuticals, Inc.72023-11-072026-05-27
Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT)
stereotactic body radiotherapy, 20 Gy in 1 fraction - Ventricular Tachycardia, Arrhythmia
Phase 2Enrolling by invitationMcGill University Health Centre/Research Institute of the McGill University Health Centre92023-07-012025-03-18
StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2
Stereotactic Arrhythmia Radiotherapy - Ventricular Tachycardia, Arrythmia, Cardiac
Phase 2RecruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)122023-05-192026-01-14
Comparison of IV Lignocain and IV Dexmedetomidine for Attenuation of Laryngoscopic Stress Response to Direct Laryngoscopy
Intravenous Dexmedetomidine infusion, Intravenous Lignocain - Tachycardia, Hypertension
Phase 2 / Phase 3CompletedShaheed Mohtarma Benazir Bhutto Institue of Trauma622023-04-132026-02-03
Venous Ethanol for Ventricular Tachycardia
Venous ethanol, Catheter ablation - Ventricular Tachycardia, Ischemic Cardiomyopathy
Phase 2RecruitingThe Methodist Hospital Research Institute1562023-04-122026-07-24
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
LQT-1213, Placebo, Dofetilide 250 μg Cap - Long QT Syndrome
Phase 1 / Phase 2TerminatedThryv Therapeutics, Inc.422023-03-122025-07-24
SBRT in Chagas Disease Ventricular Tachycardia
Stereotactic Body Radiation Therapy - Ventricular Tachycardia, Chagas Disease
Phase 1 / Phase 2UnknownUniversity of Sao Paulo General Hospital102021-07-142024-07-16
Mutation-specific Therapy for the Long QT Syndrome
Lumacaftor / Ivacaftor, Orkambi® Oral Tablet - Long QT Syndrome
Phase 2CompletedIstituto Auxologico Italiano162021-06-152025-04-25
Specialized Pacing for Patients With Congenital Heart Disease
Closed loop stimulation, Standard rate response - Congenital Heart Disease, Bradycardia Sinus
Phase 2 / Phase 3TerminatedUniversity of California, Los Angeles42021-05-092023-01-20

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Tachycardia, Ventricular (20)  ·  Arrhythmias, Cardiac (11)  ·  Tachycardia (10)  ·  Ventricular Fibrillation (7)  ·  Long QT Syndrome (6)  ·  Ventricular Premature Complexes (5)  ·  Death, Sudden, Cardiac (4)  ·  Atrial Fibrillation (3)  ·  Brugada Syndrome (3)  ·  Hypertension (3)  ·  Atrial Premature Complexes (2)  ·  Cardiomyopathies (2)  ·  Heart Arrest (2)  ·  Heart Defects, Congenital (2)  ·  Heart Diseases (2)

Broader conditions

Cardiovascular Diseases (52)  ·  Pathological Conditions, Signs and Symptoms (51)  ·  Heart Diseases (50)  ·  Pathologic Processes (50)  ·  Arrhythmias, Cardiac (41)  ·  Tachycardia (23)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Cardiovascular Abnormalities (11)  ·  Congenital Abnormalities (11)  ·  Heart Defects, Congenital (9)  ·  Cardiac Complexes, Premature (7)  ·  Vascular Diseases (6)  ·  Death (5)  ·  Death, Sudden (4)

Interventions

Radiosurgery (3)  ·  Ranolazine (3)  ·  Saline Solution (3)  ·  Sodium Chloride (3)  ·  Adrenergic beta-Antagonists (2)  ·  Catheter Ablation (2)  ·  Flecainide (2)  ·  Memantine (2)  ·  esmolol (2)  ·  Acetazolamide (1)  ·  Ajmaline (1)  ·  Atenolol (1)  ·  Atomoxetine Hydrochloride (1)  ·  Capsules (1)  ·  Cardiac Resynchronization Therapy (1)

Sponsors

Aalborg University Hospital (2)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2)  ·  Beth Israel Deaconess Medical Center (2)  ·  Boston Scientific Corporation (2)  ·  Cardurion Pharmaceuticals, Inc. (2)  ·  Milestone Pharmaceuticals Inc. (2)  ·  Thryv Therapeutics, Inc. (2)  ·  Agiana Pharmaceuticals (1)  ·  Andrea Morelli (1)  ·  AtriCure, Inc. (1)  ·  Atrium Therapeutics (1)  ·  Biosense Webster, Inc. (1)  ·  Cedars-Sinai Medical Center (1)  ·  Centre Hospitalier Universitaire, Amiens (1)  ·  Chiang Mai University (1)

Countries

United States (26)  ·  Canada (7)  ·  Italy (6)  ·  Germany (5)  ·  Netherlands (5)  ·  Denmark (4)  ·  Czechia (3)  ·  France (3)  ·  Israel (3)  ·  Spain (3)  ·  China (2)  ·  Pakistan (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Hungary (1)

Top investigators

Alvaro Alonso, MD PhD (1)  ·  Andrea Morelli, MD (1)  ·  Asma Abdus Salam, Consultant anaesthesiology (1)  ·  Chester M Hedgepeth, MD, PhD (1)  ·  David Bharucha, MD (1)  ·  David E Haines, MD (1)  ·  Eli Gang, MD (1)  ·  Elijah Behr, MD (1)  ·  Francis Plat (1)  ·  Henning R Andersen, MD, DMSc (1)  ·  James E Tisdale, BSc, PharmD (1)  ·  James Edgerton, MD (1)

Results publications

PMID 10492412, PMID 10793602, PMID 12717123, PMID 1356374, PMID 14563591, PMID 15911704, PMID 17893459, PMID 19687359, PMID 20576632, PMID 21300730, PMID 21978965, PMID 22091288, PMID 22106360, PMID 23372884, PMID 23449923, PMID 23983684, PMID 24002370, PMID 24108526, PMID 24227635, PMID 24495468, PMID 24606242, PMID 24721800, PMID 27733495, PMID 29261883, PMID 30049309, PMID 30573962, PMID 30586734, PMID 32517192, PMID 32673517, PMID 34667360, PMID 35066509, PMID 3605668, PMID 37139057, PMID 40894163, PMID 41778949, PMID 41853846, PMID 42402640, PMID 6161627, PMID 9366929, PMID 9793671, PMID 9797517

NIH funding

2016 (1), 2025 (1), R01HL059459 (1), R01HL061682 (1), UL1TR000445 (1)